Nasopharyngitis and headache were reported more with dupilumab than with placebo frequently, a finding also reported in a study of dupilumab in individuals with asthma and elevated eosinophil levels.8 Dupilumab was associated with a reduction in all assayed biomarker levels, and also with improvement of the lesional transcriptome of atopic dermatitis. The dose-dependent decrease in K16, a marker of keratinocyte proliferation and innate immunity, suggests that the epidermal abnormalities connected with atopic dermatitis may be reduced with dupilumab treatment. We also found a substantial dupilumab-associated reduction in the known level of TARC, an integral Th2 biomarker. Both levels of TARC and the modification in the levels were considerably correlated with actions of pruritus during the study.Other studies using electroencephalographic methods had found that patients identified as having generalized anxiety disorder and obsessive-compulsive disorder got heightened activity in the remaining human brain, whereas patients with anxiety attacks, panic symptoms or those put through high stress circumstances exhibited improved activity in the right hemisphere. This is the first study, nevertheless, to localize the affected regions to identify areas within each hemisphere that appear to matter.